OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Subscription and Copyright Information	656
Shearing of surface mucin saps tumor cell strength	550
Subscription and Copyright Information	266
Advisory Board and Contents	236
Subscription and Copyright Information	224
Subscription and Copyright Information	216
Subscription and Copyright Information	195
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	193
Structural asymmetry in FGF23 signaling	182
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	174
Cancer pathogenesis and phase targeting through condensate fragility	165
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	150
Compstatins: the dawn of clinical C3-targeted complement inhibition	143
Muscarinic receptors: from clinic to bench to clinic	138
Targeting complement in neurodegeneration: challenges, risks, and strategies	134
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	131
Therapeutic inhibition of ferroptosis in neurodegenerative disease	122
Structural pharmacology and mechanisms of GLP-1R signaling	109
Swinging the SWI/SNF complexes for cancer therapy	108
Direct in vivo CAR T cell engineering	104
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	103
Nemolizumab (Nemluvio®) for prurigo nodularis	103
Advisory Board and Contents	102
Engineering ACE2 decoy receptors to combat viral escapability	101
Leveraging human microbiomes for disease prediction and treatment	99

The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	99
Optogenetic engineering for precision cancer immunotherapy	94
Programmable CAR immunotherapies for neurodegenerative proteinopathies	94
Phenotypic approaches for CNS drugs	91
Advisory Board and Contents	87
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	86
Advisory Board and Contents	85
A deep dive into degrader-induced protein-protein interfaces	84
A perspective on psychedelic teratogenicity: the utility of zebrafish models	84
HSV-1 as a gene delivery platform for cancer gene therapy	83
A smart hospital-driven approach to precision pharmacovigilance	79
Ribosome-directed cancer therapies: the tip of the iceberg?	72
siRNA drug Leqvio (inclisiran) to lower cholesterol	70
Genetically engineered loaded extracellular vesicles for drug delivery	68
Close to a year in TIPS’ saddle – I am optimistic	67
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	64
Subscription and Copyright Information	64
Subscription and Copyright Information	64
Thriving as members of under-represented groups in pharmacology-related careers	64
Molecular glues evolve from serendipity to rational design	62
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	59
Mentoring future science leaders to thrive	57
Emerging approaches to induce immune tolerance to therapeutic proteins	56
Subscription and Copyright Information	55
Now you serine, now you don't	55
Bimetallic nanoadjuvants for cancer vaccines	54
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	54
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	53
Piezo1: structural pharmacology and mechanotransduction mechanisms	52
The structure, function, and pharmacology of MRGPRs	51
Autologous, allogeneic, in vivo CAR for autoimmune diseases	49
Suzetrigine for moderate to severe acute pain	49
Could dexmedetomidine be repurposed as a glymphatic enhancer?	48
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	45
Advancing non-destructive analysis of 3D printed medicines	43
The promise of targeted protein degradation approaches	42
The road less traveled: activating an oncogenic kinase	42
Advisory Board and Contents	42
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	41
Targeting metabolic vulnerabilities with advanced delivery systems	41
Treg-directed cancer immunotherapy beyond immune checkpoints: progress and opportunities	40
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
Salt-inducible kinases: new players in pulmonary arterial hypertension?	40
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	39
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	38
Subscription and Copyright Information	37
The end of the beginning in understanding SLC22 polyspecificity	37
A novel function of the M2 muscarinic receptor	37
Promising neuroimmune targets and drugs for CNS diseases	37
Advisory Board and Contents	37

Beyond G protein and arrestin: GRK2-biased β₂AR signaling	36
Validation of agent-based models of surface receptor oligomerisation	36
Frizzleds act as dynamic pharmacological entities	35
Artificial intelligence in rare diseases: toward clinical impact	35
PDE4 modulates muscle signaling in cancer cachexia	35
Targeting the assembly of biomolecules: condensate-based drug discovery	34
Monkeypox: potential vaccine development strategies	34
BTK inhibitors: past, present, and future	33
Decoding pseudouridine: an emerging target for therapeutic development	33
GPR35: from enigma to therapeutic target	31
Tackling microbial iron homeostasis: novel antimicrobial strategies	31
Protein acylations in cancer immunity: effects and therapeutic opportunities	31
Subscription and Copyright Information	31
Advisory Board and Contents	31
Advisory Board and Contents	30
Eflornithine for treatment of high-risk neuroblastoma	30
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	30
Topical difamilast for the treatment of mild-to-moderate atopic dermatitis	29
Development of PROTACs using computational approaches	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	29
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	28
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	28
Demographic diversity in platelet function and response to antiplatelet therapy	28
Recent advances in generative biology for biotherapeutic discovery	27
Metabolic regulation in normal and leukemic stem cells	27
Circulating tumor cells in precision medicine: challenges and opportunities	27
The structure, function, and pharmacology of SK channel family	26
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	26
Biologics and cardiac disease: challenges and opportunities	26
Targeting plasma membrane cholesterol as a novel anticancer therapy	26
Subscription and Copyright Information	26
Subscription and Copyright Information	25
Subscription and Copyright Information	25
Tackling chronic kidney disease in diabetic patients with finerenone	25
A novel anticancer pharmacological agent targeting mitochondrial complex I	25
Harnessing associative learning paradigms to optimize drug treatment	24
Visceral obesity and HFpEF: targets and therapeutic opportunities	24
Boosting CAR-T cell therapy through vaccine synergy	24
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	24
Recent advancements in vaccine research and development	23
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	23
Targeting sensory neuron GPCRs for peripheral neuropathic pain	23
Neutrophil extracellular traps in wound healing	23
Subscription and Copyright Information	22
Therapeutic antibodies targeting G protein-coupled receptors	22
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery	22
Challenges and opportunities associated with rare-variant pharmacogenomics	22
The ABCs of psychedelics: a preclinical roadmap for drug discovery	22
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	22
Multitargeting neuroimmune pathways: novel candidates for chronic pain relief	22
Circadian biology to advance therapeutics for mood disorders	22
Taming PRMT5–adaptor protein interactions	22
NLRP3 and pyroptosis blockers for treating inflammatory diseases	21
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	21
GABAA receptors as targets for treating affective and cognitive symptoms of depression	21
Odorant receptors as potential drug targets	20
Advisory Board and Contents	20
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	20
Subscription and Copyright Information	20
β-Arrestins and disease-linked variants: opportunities for targeted modulation	19
Glymphatic-stagnated edema induced by traumatic brain injury	19
Targeting peptide–HLA complexes for precision immunotherapy	19
GPCR-dependent and -independent arrestin signaling	19
Potential for targeting small heat shock protein modifications	19
Advisory Board and Contents	18
Bridging the gap in neuropsychiatric translational research	18
Celiac disease: mechanisms and emerging therapeutics	18
Targeted protein degrader development for cancer: advances, challenges, and opportunities	18
Malolactone strikes: K-Ras-G12D's Achilles' heel	18
Advisory Board and Contents	18
Subscription and Copyright Information	18
The structure and function of YTHDF epitranscriptomic m6A readers	18
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18
Advisory Board and Contents	18